Bausch Health Companies Inc 2025年季度报告

Washington,D.C. 20549 FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the Quarterly Period EndedMarch 31, 2025OR☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period fromto Commission File Number:001-14956 Bausch Health Companies Inc.(Exact name of registrant as specified in its charter) (514)744-6792(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or15(d) of theSecurities Exchange Act of 1934 during the preceding 12months (orfor such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T during the preceding 12months (orfor such shorter period that the registrant wasrequired to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smallerreporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☒Accelerated filer☐Non-accelerated filer☐Smaller reportingcompany☐Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (asdefined in Rule12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicabledate. Common shares, no par value—369,550,086shares outstanding as of April 25, 2025. BAUSCH HEALTH COMPANIESINC.FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH31, 2025 INDEX PartI.Financial Information Item1.Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance Sheets as of March 31, 2025 and December31, 2024Condensed Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2025 and 2024Condensed Consolidated Statements of Shareholders’ Deficit for the three months ended March 31, 2025 and 2024Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024Notes to the Condensed Consolidated Financial StatementsItem2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3.Quantitative andQualitative Disclosures About Market RiskItem4.Controls and ProceduresPartII.Other InformationItem1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.ExhibitsSignatures BAUSCH HEALTH COMPANIESINC.FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH31, 2025 Introductory Note Except where the context otherwise requires, all references in this Quarterly Report on Form10-Q for the quarterly period endedMarch31, 2025 (this “Form 10-Q”) tothe “Company”, “we”, “us”, “our” or similar words or phrases are to Bausch HealthCompaniesInc. and its subsidiaries, taken together. In this Form10-Q, references to“$” are to UnitedStates (“U.S.”) dollars,references to “€” are to Euros and references to “CAD” are to Canadian dollars. Unless otherwise indicated, the statistical andfinancial data contained in this Form10-Q are presented as of March31, 2025. Forward-Looking Statements This Form10-Q contains forward-looking statements within the meaning of Section27A of the Securities Act of 1933, asamended, and Section21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within themeaning of applicable Canadian securities laws (collectively, “forward-looking statements”), as described in more detail under theheading “Forward-Looking Statements” in Item 2 of Part I of this Form 10-Q. Additional information about these factors and aboutthe material factors or assumptions underlying such forward-looking statements may be found (i) in our Annual Report on Form 10-Kfor the year ended December31, 2024, filed on February19, 2025, under Item1A. “Risk Factors”; (ii) under Item 1A. “RiskFactors” of Part II of this Form 10-Q; and (iii) in the Company’s other filings with the U.S. Securities and Exchange Commission (the“SEC”) and the Canadian Securities Administrators (the “CSA”). When relying on our forward-looking statements to make de